Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

However, treatment with benralizumab did not result in fewer or less severe dysphagia symptoms than placebo. (Funded by AstraZeneca; MESSINA ClinicalTrials.gov number, NCT04543409.) The trial was ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). The FDA has approved an expanded indication of AstraZeneca’s benralizumab ...

Opens in a new tab or window The FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with polyangiitis (EGPA), drugmaker AstraZeneca ...

and Fasenra (benralizumab) are positioned for indication expansion into severe asthma and chronic obstructive pulmonary disorder (COPD), respectively, during 2025. Sarin said AstraZeneca’s ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab ... study was supported by AstraZeneca.

Benralizumab, marketed by Astrazeneca (AZN), targets a specific type of white blood cells, called eosinophils, which is responsible for inflammation and damage in the lungs. The study involved 158 ...

In the study, after 28 days of treatment respiratory symptoms were found to be better with benralizumab. After 90 days, there were four times fewer people in the AstraZeneca drug group that failed ...